SCHEMBL20119906

SCHEMBL20119906

N#Cc1c[nH]c2nc(Cl)nc(NCc3ccco3)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
CHUK O15111 3/20 0.50
KDM4E B2RXH2 7/20 0.47
HSD17B10 Q99714 6/20 0.47
ALDH1A1 P00352 5/20 0.47
GAA P10253 4/20 0.47
CASP1 P29466 1/20 0.47
KMT2A Q03164 5/20 0.44
LRRK2 Q5S007 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
MAPK1 P28482 2/20 0.42
MEN1 O00255 2/20 0.42
HTT P42858 1/20 0.42
BLM P54132 1/20 0.42
HPGD P15428 4/20 0.42
ALOX15 P16050 2/20 0.42
EED O75530 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119882 0.84 SMN1; SMN2 (0.58) SMN1; SMN2KDM4EHSD17B10ALDH1A1KMT2A
SCHEMBL20119666 0.83 SMN1; SMN2 (0.57) SMN1; SMN2KDM4EHSD17B10ALDH1A1KMT2A
SCHEMBL20120006 0.82 SMN1; SMN2 (0.56) SMN1; SMN2KDM4EHSD17B10ALDH1A1KMT2A
SCHEMBL20119987 0.82 SMN1; SMN2 (0.53) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA
SCHEMBL20344047 0.81 CHUK (0.74) CHUKKDM4EHSD17B10ALDH1A1GAA
SCHEMBL20119653 0.81 SMN1; SMN2 (0.54) SMN1; SMN2KDM4EHSD17B10ALDH1A1KMT2A
SCHEMBL20119638 0.80 SMN1; SMN2 (0.53) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA
SCHEMBL20119905 0.78 SMN1; SMN2 (0.51) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA
SCHEMBL20119675 0.78 SMN1; SMN2 (0.51) SMN1; SMN2KDM4EHSD17B10ALDH1A1KMT2A
SCHEMBL20119970 0.78 SMN1; SMN2 (0.51) SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885CHUK 2130/4885KDM4E 3687/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885CHUK 2130/4885KDM4E 3687/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885CHUK 2130/4885KDM4E 3687/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885CHUK 2130/4885KDM4E 3687/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885CHUK 2130/4885KDM4E 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.